The clindamycin phosphate 1.2% combined with tretinoin 0.025% gel formulation (CTG) is an FDA-approved topical treatment for acne vulgaris in patients aged 12 years and older. Primarily indicated for managing moderate comedonal and mild to moderate papulopustular acne, which collectively accounts for over 50% of acne cases, CTG offers a fixed and stable combination for effective treatment.

In cases of nodulocystic acne, CTG can be complemented with systemic antiacne therapy like isotretinoin. This formulation synergizes the anti-inflammatory and antibacterial properties of clindamycin with the well-established comedolytic and anticomedogenic effects of tretinoin (all-trans retinoic acid). The incorporation of clindamycin enhances tretinoins comedolytic efficacy, particularly in moderate to severe facial acne.

The combination of tretinoins comedolytic activity and clindamycins anti-inflammatory efficacy accelerates the resolution of various acne lesions without compromising the safety of either component. Notably, the discontinuation rates due to adverse events related to CTG are low, not exceeding 1%. However, it is important to note that the safety of CTG use during pregnancy has not been conclusively established.

CTG is specifically designed to improve effectiveness while minimizing irritation. With once-daily application, CTG offers rapid and dual effects, ensuring good tolerability. This regimen positively impacts the duration of the disease, enhances patient compliance and contributes to overall therapy cost-effectiveness. Health care providers are encouraged to consider CTG as a valuable option in the comprehensive management of acne vulgaris in eligible patients.

Source:Abdel-Naser MB, Zouboulis CC. Expert Opin Pharmacother. 2008;9(16):2931-7.